Thienopyridine and furopyridine kinase inhibitors

A compound of formula (I)

• or a therapeutically acceptable salt thereof, wherein
• X is S;
• Z is C;
• R1 is selected from the group consisting of alkenyl, alkoxyalkynyl, alkoxycarbonyl, alkoxycarbonylalkenyl, alkoxycarbonylalkyl, alkoxycarbonylalkynyl, alkynyl, arylalkenyl, arylalkyl, arylalkynyl, aryloxyalkyl, aryloxyalkynyl, arylsulfanylalkyl, arylsulfanylalkynyl, arylsulfonyloxyalkenyl, carboxy, carboxyalkenyl, carboxyalkyl, carboxyalkynyl, cyanoalkenyl, cyanoalkyl, cyanoalkynyl, cycloalkyl, cycloalkylalkoxyalkynyl, cycloalkylalkenyl, cycloalkylalkynyl, formylalkenyl, formylalkyl, haloalkyl, benzothiazolyl, benzothienyl, benzoxazolyl, furyl, indolyl, pyrazolyl, pyrrolyl, thienyl, benzoheteroarylalkenyl, heteroarylalkyl, heteroarylalkynyl, heteroarylcarbonyl, heteroarylcarbonylalkenyl, heteroarylcarbonylalkyl, heterocyclyl, heterocyclylalkenyl, heterocyclylalkyl, heterocyclylalkylcarbonyl, heterocyclylalkynyl, heterocyclylcarbonyl, heterocyclylcarbonylalkenyl, heterocyclylcarbonylalkyl, heterocyclyloxyalkenyl, hydroxyalkenyl, hydroxyalkyl, hydroxyalkynyl, nitroalkenyl, nitroalkyl, and nitroalkynyl;
• R2 is selected from the group consisting of hydrogen and alkyl;
• R3 is aryl, wherein the aryl is substituted with LR4 and optionally substituted with one or two additional substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, heteroaryl, heterocyclyl, hydroxy, hydroxyalkyl, and NRaRb;
• L is (CH2)mN(R5)C(O)N(R6)(CH2)n, wherein m and n are independently 0 or 1, and wherein each group is drawn with its right end attached to R4;
• R4 is selected from the group consisting of aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
• and
• R5 and R6 are independently selected from the group consisting of hydrogen and alkyl.